Repligen Corp

Repligen Corp Stock Forecast & Price Prediction

Live Repligen Corp Stock (RGEN) Price
$140.70

6

Ratings

  • Buy 5
  • Hold 1
  • Sell 0
Disclaimer : Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance. This information is for educational purposes only and should not be construed as advice to buy or sell any security.

Stock Price

$140.70

P/E Ratio

511.11

Volume Traded Today

$543,900

Dividend

Dividends not available for RGEN

52 Week High/low

211.13/113.50

Repligen Corp Market Cap

$7.88B

๐Ÿ›‘ Alert: These ten stocks could have higher potential than $RGEN ๐Ÿ›‘

Before you buy RGEN you'll want to see this list of ten stocks that have huge potential. Want to see if RGEN made the cut? Enter your email below

RGEN Summary

From what 6 stock analysts predict, the share price for Repligen Corp (RGEN) might increase by 37.21% in the next year. This is based on a 12-month average estimation for RGEN. Price targets go from $160 to $225. The majority of stock analysts believe RGEN is a buy. Please note analyst price targets are not guaranteed and could be missed completely.

RGEN Analyst Ratings

RGEN is a stock in Healthcare which has been forecasted to be worth $193.06 as an average. On the higher end, the forecast price is $225 USD by Raghuram Selvaraju from HC Wainwright & Co. and on the lower end RGEN is forecasted to be $160 by from .

RGEN stock forecast by analyst

These are the latest 20 analyst ratings of RGEN.

Analyst/Firm

Rating

Price Target

Change

Date

Conor McNamara
RBC Capital

Outperform

$205

Reiterates

Sep 26, 2024
Brandon Couillard
Wells Fargo

Overweight

$180

Initiates

Aug 27, 2024
Robert Wasserman
Benchmark

Hold


Reiterates

Aug 5, 2024
Elizabeth Garcia
UBS

Buy

$185

Maintains

Jul 31, 2024
Conor McNamara
RBC Capital

Outperform

$190

Reiterates

Jul 31, 2024
Rachel Vatnsdal
JP Morgan

Overweight

$200

Maintains

Jul 31, 2024
Jacob Johnson
Stephens & Co.

Overweight

$170

Reiterates

Jul 30, 2024
Justin Bowers
Deutsche Bank

Buy

$155

Upgrade

Jun 26, 2024
Subbu Nambi
Guggenheim

Neutral


Initiates

Jun 18, 2024
Rachel Vatnsdal
JP Morgan

Overweight

$200

Maintains

May 2, 2024
Daniel Arias
Stifel

Buy

$207

Maintains

Feb 22, 2024
Paul Knight
Keybanc

Overweight

$220

Maintains

Feb 15, 2024
Tycho Peterson
JP Morgan

Overweight

$210

Maintains

Dec 20, 2023
Robert Wasserman
Benchmark

Hold


Downgrade

Dec 4, 2023
Elizabeth Garcia
UBS

Buy

$170

Maintains

Nov 2, 2023
Paul Knight
Keybanc

Overweight

$210

Maintains

Nov 1, 2023
Conor McNamara
RBC Capital

Outperform

$200

Maintains

Nov 1, 2023
Daniel Arias
Stifel

Buy

$165

Maintains

Nov 1, 2023
Tycho Peterson
JP Morgan

Overweight

$180

Maintains

Oct 17, 2023
Conor McNamara
RBC Capital

Outperform

$191

Reiterates

Sep 8, 2023

RGEN Company Information

What They Do: Develops bioprocessing technologies for drug manufacturing.

Business Model: The company generates revenue by offering a range of bioprocessing technologies and systems that are essential for biological drug manufacturing. This includes high-value products such as chromatography columns, filtration systems, and process analytics tools, which are sold to biopharmaceutical companies, life sciences organizations, and contract manufacturers.

Other Information: Repligen Corporation has a strong international presence and collaborates with other firms, like Navigo Proteins GmbH, to enhance its product offerings. Established in 1981 and headquartered in Waltham, Massachusetts, the company continues to innovate in the bioprocessing sector, addressing critical needs in the drug development process.
RGEN
Repligen Corp (RGEN)

When did it IPO

1990

Staff Count

1,783

Country

United States

Sector/Industry

Healthcare/Medical Instruments & Supplies

CEO

Mr. Olivier Loeillot

Market Cap

$7.88B

Repligen Corp (RGEN) Financial Data

In 2023, RGEN generated $638.8M in revenue, which was a decrease of -20.31% from the previous year. This can be seen as a signal that RGEN's business is declining, and its share price could be worth less in the future. However, if the company grows faster (or slower) than expected, this could also have a major impact on the future share price.

Revenue From 2020

$366.3M

Revenue From 2021

$670.5M

83.08 %
From Previous Year

Revenue From 2022

$801.5M

19.54 %
From Previous Year

Revenue From 2023

$638.8M

-20.31 %
From Previous Year
  • Revenue TTM $602.4M
  • Operating Margin TTM 1.6%
  • Gross profit TTM $284.8M
  • Return on assets TTM 0.2%
  • Return on equity TTM -0.1%
  • Profit Margin -0.3%
  • Book Value Per Share 35.53%
  • Market capitalisation $7.88B
  • Revenue for 2021 $670.5M
  • Revenue for 2022 $801.5M
  • Revenue for 2023 $638.8M
  • EPS this year (TTM) $-0.03

Repligen Corp (RGEN) Latest News

News Image

Tue, 05 Nov 2024

Sentiment - NEUTRAL

Source - GlobeNewsWire

Summary - Repligen Corporation (NASDAQ:RGEN) will present at three upcoming investor conferences, highlighting its focus on bioprocessing technology.

Why It Matters - Repligen Corporation's participation in investor conferences can boost visibility, attract potential investors, and signal confidence in its growth prospects, impacting stock performance.

News Image

Tue, 22 Oct 2024

Sentiment - NEUTRAL

Source - Zacks Investment Research

Summary - Repligen (RGEN) is not expected to meet earnings expectations in its upcoming report due to lacking key performance indicators. Investors should prepare for this outcome.

Why It Matters - Repligen's lack of key ingredients for an earnings beat may indicate weaker performance, potentially leading to a decline in stock price and investor confidence.

News Image

Mon, 14 Oct 2024

Sentiment - NEUTRAL

Source - GlobeNewsWire

Summary - The global Peptide Therapeutics market was valued at $42.1B in 2023 and is projected to reach $56.2B by 2030, with a CAGR of 4.2%, driven by technological advances in therapy development.

Why It Matters - The projected growth of the peptide therapeutics market indicates potential investment opportunities, driven by technological advancements and increasing demand for targeted therapies.

News Image

Tue, 24 Sep 2024

Sentiment - NEUTRAL

Source - GlobeNewsWire

Summary - Repligen Corporation (NASDAQ:RGEN) has opened the Repligen Training & Innovation Center at its Waltham headquarters, enhancing its focus on bioprocessing technology.

Why It Matters - The launch of the Repligen Training & Innovation Center enhances Repligen's bioprocessing capabilities, potentially driving growth, innovation, and market competitiveness, which can positively impact stock performance.

News Image

Fri, 23 Aug 2024

Sentiment - NEUTRAL

Source - GlobeNewsWire

Summary - Repligen Corporation (NASDAQ:RGEN) will present at the Wells Fargo Healthcare Conference from September 4-6, with CEO Olivier Loeillot speaking on September 6 at 8:45 a.m. ET.

Why It Matters - Repligen's presentation at a key healthcare conference could influence investor sentiment and stock performance, showcasing its bioprocessing advancements and leadership in the sector.

News Image

Fri, 16 Aug 2024

Sentiment - POSITIVE

Source - Reuters

Summary - Repligen has made an acquisition offer to Maravai LifeSciences Holdings, which has a market value of $2.2 billion, according to sources.

Why It Matters - Repligen's acquisition offer for Maravai could signal growth opportunities in the biotech sector, potentially increasing Repligen's market share and affecting stock valuations.

...

RGEN Frequently asked questions

The highest forecasted price for RGEN is $225 from Raghuram Selvaraju at HC Wainwright & Co..

The lowest forecasted price for RGEN is $160 from from

The RGEN analyst ratings consensus are 5 buy ratings, 1 hold ratings, and 0 sell ratings.